Search hospitals > Ontario > BARRIE

Royal Victoria Regional Health Centre

Claim this profile
BARRIE, Ontario L4M 6M2
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Colorectal Cancer
106 reported clinical trials
8 medical researchers
Photo of Royal Victoria Regional Health Centre in BARRIEPhoto of Royal Victoria Regional Health Centre in BARRIEPhoto of Royal Victoria Regional Health Centre in BARRIE

Summary

Royal Victoria Regional Health Centre is a medical facility located in BARRIE, Ontario. This center is recognized for care of Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Colorectal Cancer and other specialties. Royal Victoria Regional Health Centre is involved with conducting 106 clinical trials across 111 conditions. There are 8 research doctors associated with this hospital, such as Adam Gladwish, MD, Giulio Didiodato, MD, Christiaan S. Stevens, and Derek Nay.

Area of expertise

1Breast Cancer
Global Leader
Royal Victoria Regional Health Centre has run 26 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
ER positive
Stage IV
2Cancer
Global Leader
Royal Victoria Regional Health Centre has run 13 trials for Cancer. Some of their research focus areas include:
Stage III
Stage IV
Stage I

Top PIs

Clinical Trials running at Royal Victoria Regional Health Centre

Breast Cancer
Melanoma
Lymphoma
B-Cell Leukemia
Skin Cancer
Non-Small Cell Lung Cancer
Kidney Tumors
Prostate Cancer
Lymphocytic Leukemia
Leukemia
Image of trial facility.

PF-07220060 + Fulvestrant

for Advanced Breast Cancer

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: are 18 years of age or older; are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; have advanced or metastatic breast cancer after taking other treatments before this study; have not taken or need to take medications that are not allowed by the study protocol; do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: Fulvestrant alone taken as shot into the muscle. Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. the study doctor thinks the participant is no longer benefitting from the study medicine. has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. the participant chooses to stop taking part.
Recruiting2 awards Phase 3
Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Giredestrant vs. Fulvestrant

for Advanced Breast Cancer

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
Recruiting2 awards Phase 38 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Royal Victoria Regional Health Centre?
Royal Victoria Regional Health Centre is a medical facility located in BARRIE, Ontario. This center is recognized for care of Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Colorectal Cancer and other specialties. Royal Victoria Regional Health Centre is involved with conducting 106 clinical trials across 111 conditions. There are 8 research doctors associated with this hospital, such as Adam Gladwish, MD, Giulio Didiodato, MD, Christiaan S. Stevens, and Derek Nay.